Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19 : A Multicenter Observational Study
Thieme. All rights reserved..
BACKGROUND: It is still unclear if patients with community-acquired pneumonia (CAP) and coronavirus disease 2019 (COVID-19) have different rate, typology, and impact of thrombosis on survival.
METHODS: In this multicenter observational cohort study, 1,138 patients, hospitalized for CAP (n = 559) or COVID-19 (n = 579) from seven clinical centers in Italy, were included in the study. Consecutive adult patients (age ≥ 18 years) with confirmed COVID-19-related pneumonia, with or without mechanical ventilation, hospitalized from March 1, 2020 to April 30, 2020, were enrolled. COVID-19 was diagnosed based on the World Health Organization interim guidance. Patients were followed-up until discharge or in-hospital death, registering the occurrence of thrombotic events including ischemic/embolic events.
RESULTS: During the in-hospital stay, 11.4% of CAP and 15.5% of COVID-19 patients experienced thrombotic events (p = 0.046). In CAP patients all the events were arterial thromboses, while in COVID-19 patients 8.3% were venous and 7.2% arterial thromboses.During the in-hospital follow-up, 3% of CAP patients and 17% of COVID-19 patients died (p < 0.001). The highest mortality rate was found among COVID-19 patients with thrombotic events (47.6 vs. 13.4% in thrombotic-event-free patients; p < 0.001). In CAP, 13.8% of patients experiencing thrombotic events died versus 1.8% of thrombotic event-free ones (p < 0.001). A multivariable Cox-regression analysis confirmed a higher risk of death in COVID-19 patients with thrombotic events (hazard ratio: 2.1; 95% confidence interval: 1.4-3.3; p < 0.001).
CONCLUSION: Compared with CAP, COVID-19 is characterized by a higher burden of thrombotic events, different thrombosis typology and higher risk of thrombosis-related in-hospital mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:122 |
|---|---|
| Enthalten in: |
Thrombosis and haemostasis - 122(2022), 2 vom: 15. Feb., Seite 257-266 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cangemi, Roberto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Trial |
|---|
| Anmerkungen: |
Date Completed 21.02.2022 Date Revised 09.08.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1055/a-1692-9939 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332964191 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332964191 | ||
| 003 | DE-627 | ||
| 005 | 20231225220647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1055/a-1692-9939 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332964191 | ||
| 035 | |a (NLM)34758488 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cangemi, Roberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19 |b A Multicenter Observational Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.02.2022 | ||
| 500 | |a Date Revised 09.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Thieme. All rights reserved. | ||
| 520 | |a BACKGROUND: It is still unclear if patients with community-acquired pneumonia (CAP) and coronavirus disease 2019 (COVID-19) have different rate, typology, and impact of thrombosis on survival | ||
| 520 | |a METHODS: In this multicenter observational cohort study, 1,138 patients, hospitalized for CAP (n = 559) or COVID-19 (n = 579) from seven clinical centers in Italy, were included in the study. Consecutive adult patients (age ≥ 18 years) with confirmed COVID-19-related pneumonia, with or without mechanical ventilation, hospitalized from March 1, 2020 to April 30, 2020, were enrolled. COVID-19 was diagnosed based on the World Health Organization interim guidance. Patients were followed-up until discharge or in-hospital death, registering the occurrence of thrombotic events including ischemic/embolic events | ||
| 520 | |a RESULTS: During the in-hospital stay, 11.4% of CAP and 15.5% of COVID-19 patients experienced thrombotic events (p = 0.046). In CAP patients all the events were arterial thromboses, while in COVID-19 patients 8.3% were venous and 7.2% arterial thromboses.During the in-hospital follow-up, 3% of CAP patients and 17% of COVID-19 patients died (p < 0.001). The highest mortality rate was found among COVID-19 patients with thrombotic events (47.6 vs. 13.4% in thrombotic-event-free patients; p < 0.001). In CAP, 13.8% of patients experiencing thrombotic events died versus 1.8% of thrombotic event-free ones (p < 0.001). A multivariable Cox-regression analysis confirmed a higher risk of death in COVID-19 patients with thrombotic events (hazard ratio: 2.1; 95% confidence interval: 1.4-3.3; p < 0.001) | ||
| 520 | |a CONCLUSION: Compared with CAP, COVID-19 is characterized by a higher burden of thrombotic events, different thrombosis typology and higher risk of thrombosis-related in-hospital mortality | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 700 | 1 | |a Calvieri, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a Falcone, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Cipollone, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccarelli, Giancarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Pignatelli, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a D'Ardes, Damiano |e verfasserin |4 aut | |
| 700 | 1 | |a Pirro, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Alessandri, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Lichtner, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a D'Ettorre, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Aronica, Raissa |e verfasserin |4 aut | |
| 700 | 1 | |a Rocco, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Venditti, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Romiti, Giulio Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Tiseo, Giusy |e verfasserin |4 aut | |
| 700 | 1 | |a Taliani, Gloria |e verfasserin |4 aut | |
| 700 | 1 | |a Menichetti, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Pugliese, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Mastroianni, Claudio Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Violi, Francesco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Thrombosis and haemostasis |d 1979 |g 122(2022), 2 vom: 15. Feb., Seite 257-266 |w (DE-627)NLM000103896 |x 2567-689X |7 nnns |
| 773 | 1 | 8 | |g volume:122 |g year:2022 |g number:2 |g day:15 |g month:02 |g pages:257-266 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1055/a-1692-9939 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 122 |j 2022 |e 2 |b 15 |c 02 |h 257-266 | ||